isoniazid
| Product dosage: 300mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.50 | $45.06 (0%) | 🛒 Add to cart |
| 120 | $0.46 | $60.08 $55.07 (8%) | 🛒 Add to cart |
| 180 | $0.42 | $90.12 $75.10 (17%) | 🛒 Add to cart |
| 270 | $0.39 | $135.17 $106.14 (21%) | 🛒 Add to cart |
| 360 | $0.38
Best per pill | $180.23 $136.17 (24%) | 🛒 Add to cart |
Synonyms
| |||
Isoniazid remains one of those foundational tuberculosis drugs that somehow never gets the spotlight it deserves. When I first started in pulmonary medicine back in ‘98, we had this 65-year-old patient, Mr. Henderson, who’d failed multiple TB regimens. His sputum cultures just kept coming back positive, and we were running out of options. That’s when we decided to push isoniazid dosing higher than typical, monitoring his liver enzymes like hawks. Within six weeks, his cultures finally cleared. That case taught me more about this drug’s potential than any textbook ever could.
Isoniazid: Essential First-Line Tuberculosis Treatment - Evidence-Based Review
1. Introduction: What is Isoniazid? Its Role in Modern Medicine
Isoniazid, often abbreviated INH, represents one of the most significant discoveries in tuberculosis therapy. This synthetic antimycobacterial agent has been the backbone of TB treatment since its introduction in 1952. What many junior residents don’t appreciate is how isoniazid completely transformed TB mortality rates - we went from sanatoriums filled with chronic patients to effective outpatient management. The World Health Organization still considers isoniazid preventive therapy crucial for TB control in high-burden countries.
I remember arguing with our infectious disease team about isoniazid monotherapy for latent TB back in 2005. Dr. Chen kept insisting the hepatotoxicity risk outweighed benefits, but our data from the immigrant screening clinic showed otherwise. We tracked 400 patients over three years - only 2% developed significant transaminase elevations, and all resolved with dose adjustment. That experience shaped how I now approach isoniazid risk-benefit discussions.
2. Key Components and Pharmaceutical Properties
The molecular structure of isoniazid is deceptively simple - isonicotinic acid hydrazide - but its activity against Mycobacterium tuberculosis is remarkably specific. We’ve found that the hydrazide moiety is absolutely critical for the prodrug activation process. What’s fascinating is how different formulations affect bioavailability. The standard 300mg tablet achieves peak serum concentrations within 1-2 hours, but we’ve noticed significant interpatient variability in our clinic population.
I had this one patient, Maria, who kept having breakthrough symptoms despite documented adherence. We finally checked her isoniazid levels and found her Cmax was 40% lower than expected. Switched her to liquid formulation on empty stomach, and her levels normalized. Taught me never to assume bioavailability.
The pyridoxine component deserves special mention here. We learned the hard way about peripheral neuropathy risks early in my career. Now I automatically co-prescribe pyridoxine 25-50mg daily for everyone on isoniazid, especially diabetics and alcohol users. The biochemistry department would tell you it’s about competitive inhibition of pyridoxal phosphokinase, but clinically, it’s about preventing debilitating nerve damage that can ruin treatment adherence.
3. Mechanism of Action: Scientific Substantiation
The mechanism of isoniazid action is beautifully specific - it inhibits mycolic acid synthesis by targeting the enoyl-acyl carrier protein reductase (InhA). This essentially disrupts the bacterial cell wall construction in replicating organisms. What’s clinically relevant is that this explains why isoniazid is primarily bactericidal against actively dividing mycobacteria but has limited activity against dormant persisters.
We had this interesting case last year where a patient’s isolate showed borderline resistance. The microbiology lab did whole genome sequencing and found a katG mutation that reduced isoniazid activation. This is why understanding the activation pathway matters - isoniazid requires bacterial catalase-peroxidase (KatG) to convert to its active form. No activation, no drug activity.
The resident I’m training now asked why we don’t see more cross-resistance with other TB drugs. The answer lies in this unique mechanism - unlike rifampin which targets RNA polymerase or fluoroquinolones targeting DNA gyrase, isoniazid hits this very specific mycobacterial pathway. This specificity is both its strength and weakness, as resistance can develop through single mutations.
4. Indications for Use: What is Isoniazid Effective For?
Isoniazid for Active Tuberculosis Treatment
Always in combination therapy, never alone. The standard RIPE regimen (rifampin, isoniazid, pyrazinamide, ethambutol) relies on isoniazid for its potent early bactericidal activity. We monitor response closely in the first two months - if we don’t see clinical improvement, we start suspecting resistance.
Isoniazid for Latent Tuberculosis Infection
This is where dosing gets interesting. The classic 300mg daily for 9 months remains gold standard, but we’ve had good results with 900mg twice weekly directly observed therapy in our homeless population clinic. The 3-month rifapentine-isoniazid regimen has better completion rates but more hepatotoxicity in our experience.
Isoniazid for TB Prevention in HIV
The CIPRA SA study changed our practice here. We now routinely offer isoniazid preventive therapy to all HIV-positive patients in high TB prevalence areas, regardless of TST status. The reduction in mortality is significant enough that the ethics committee approved this as standard care last year.
5. Instructions for Use: Dosage and Course of Administration
| Indication | Dosage | Frequency | Duration | Special Instructions |
|---|---|---|---|---|
| Active TB | 5mg/kg (max 300mg) | Daily | 6-9 months | Always combine with other TB drugs |
| Latent TB (daily) | 300mg | Daily | 9 months | Monitor liver enzymes monthly |
| Latent TB (twice weekly) | 900mg | Twice weekly | 9 months | Directly observed therapy recommended |
| Pediatric dosing | 10-15mg/kg | Daily | Varies by indication | Maximum 300mg daily |
The timing of administration matters more than we sometimes acknowledge. I’ve had patients take isoniazid with high-fat meals and show reduced absorption. We now specifically instruct empty stomach administration, though we make exceptions for GI intolerance.
One of our nursing home patients, Mr. Goldberg, developed confusion on isoniazid. We initially thought it was dementia progression, but his daughter noticed it correlated with his TB treatment start. Turned out he was taking his isoniazid at bedtime on empty stomach and having neurotoxic effects. Switched to morning dosing with light breakfast, symptoms resolved. Little things matter.
6. Contraindications and Drug Interactions
The hepatotoxicity risk is real - we see about 10-20% of patients develop asymptomatic transaminase elevations, but severe hepatitis occurs in 1-2%. Our clinic protocol now includes baseline LFTs, then monthly for first 3 months, then every 3 months. The old teaching was to discontinue at AST/ALT >3x ULN, but we’re more nuanced now - if asymptomatic, we might continue with closer monitoring.
Drug interactions that caught us unexpectedly:
- Phenytoin levels increase significantly with isoniazid
- Carbamazepine toxicity risk due to CYP inhibition
- Warfarin potentiation - we had a patient whose INR jumped to 8.2
The acute hepatitis case we had in 2018 taught us valuable lessons. Patient was on isoniazid, rifampin, and drinking alcohol “socially.” His bilirubin hit 15, AST 800. Survived, but spent weeks in ICU. Now we’re much stricter about alcohol counseling.
Absolute contraindications include previous severe reaction to isoniazid, acute liver disease, and pregnancy (relative - we weigh risks vs benefits). The pregnancy category C designation makes decision-making challenging sometimes.
7. Clinical Studies and Evidence Base
The British Medical Research Council trials from the 1970s still inform much of our practice. Their demonstration of isoniazid’s early bactericidal activity laid the foundation for modern short-course chemotherapy. More recently, the PREVENT TB trial showed the 3-month weekly rifapentine-isoniazid regimen was non-inferior to 9 months daily isoniazid for latent TB, with similar completion rates.
What’s interesting is the emerging data on pharmacogenomics. We’re participating in a multicenter study looking at NAT2 acetylator status and isoniazid toxicity. Preliminary findings suggest slow acetylators have higher risk of peripheral neuropathy but lower risk of hepatitis. This might explain some of our clinical observations about variable side effect profiles.
The TBTC Study 26 actually changed my practice regarding monitoring. They found that routine monthly LFT monitoring didn’t prevent severe hepatitis compared to symptom-based monitoring alone. We’ve relaxed our monitoring protocol accordingly for low-risk patients.
8. Comparing Isoniazid with Similar TB Drugs and Regimen Selection
The comparison with rifampin is inevitable - both are cornerstone drugs, but with different roles. Isoniazid has superior early bactericidal activity, while rifampin is better for sterilizing effects and preventing relapse. This complementary action is why they work so well together.
When we have to choose between isoniazid and other drugs for latent TB, the decision matrix gets complex. Rifampin alone for 4 months has lower hepatotoxicity but more drug interactions. The 3-month isoniazid-rifapentine regimen has better completion but higher cost. There’s no one-size-fits-all answer - we individualize based on patient factors.
Our clinic developed a decision aid that walks patients through these choices. Visual analog scales showing efficacy vs side effect risks, pill burden, duration - it’s helped adherence tremendously. One patient told me “I finally understand why I’m taking what I’m taking.”
9. Frequently Asked Questions about Isoniazid
What monitoring is required during isoniazid treatment?
We check baseline LFTs, then clinically monitor for symptoms of hepatitis. Routine monthly LFTs for first 3 months, then less frequently if stable. More frequent monitoring for high-risk patients.
Can isoniazid be taken during pregnancy?
Category C - we use when benefits outweigh risks. Active TB always requires treatment. For latent TB, we often defer until postpartum unless high exposure risk.
How should missed doses be handled?
If remembering within same day, take immediately. If next day, skip missed dose and continue regular schedule. Never double dose.
What foods or supplements interact with isoniazid?
Tyramine-rich foods may cause mild reactions. Pyridoxine supplementation recommended to prevent neuropathy. Antacids may reduce absorption.
When should isoniazid be discontinued?
Severe hepatitis (symptoms + LFT elevation), hypersensitivity reactions, or severe peripheral neuropathy unresponsive to pyridoxine.
10. Conclusion: Validity of Isoniazid Use in Clinical Practice
Despite being one of our oldest TB drugs, isoniazid remains irreplaceable in global tuberculosis control. The benefit-risk profile strongly favors use in both active and latent TB when properly monitored. The key is individualization - there’s no single right way to use isoniazid, but many right ways tailored to specific patient circumstances.
Looking back over 25 years of using this drug, what strikes me is how our understanding has evolved. We went from fearing hepatotoxicity to understanding its predictable patterns. From rigid protocols to flexible, patient-centered approaches. The recent pharmacogenomic research promises even more personalized dosing in the future.
Just last month, I saw Mr. Henderson’s grandson in clinic - same family, different era. Starting isoniazid preventive therapy after college TB screening. The grandfather survived disseminated TB in the pre-isoniazid era, the grandson gets prevention before infection. That’s progress. Isoniazid, despite its age, remains fundamental to that progress. The research continues, the clinical experience accumulates, but the bottom line remains: when used wisely, isoniazid saves lives. We’ve come a long way since those early days of uncertainty, and the drug that started it all still deserves our respect and understanding.